Bioprosthesis: Prosthesis, usually heart valve, composed of biological material and whose durability depends upon the stability of the material after pretreatment, rather than regeneration by host cell ingrowth. Durability is achieved 1, mechanically by the interposition of a cloth, usually polytetrafluoroethylene, between the host and the graft, and 2, chemically by stabilization of the tissue by intermolecular linking, usually with glutaraldehyde, after removal of antigenic components, or the use of reconstituted and restructured biopolymers.Heart Valve Prosthesis: A device that substitutes for a heart valve. It may be composed of biological material (BIOPROSTHESIS) and/or synthetic material.Heart Valve Prosthesis Implantation: Surgical insertion of synthetic material to repair injured or diseased heart valves.Aortic Valve: The valve between the left ventricle and the ascending aorta which prevents backflow into the left ventricle.Tricuspid Valve Stenosis: The pathologic narrowing of the orifice of the TRICUSPID VALVE. This hinders the emptying of RIGHT ATRIUM leading to elevated right atrial pressure and systemic venous congestion. Tricuspid valve stenosis is almost always due to RHEUMATIC FEVER.Aortic Valve Stenosis: A pathological constriction that can occur above (supravalvular stenosis), below (subvalvular stenosis), or at the AORTIC VALVE. It is characterized by restricted outflow from the LEFT VENTRICLE into the AORTA.Prosthesis Design: The plan and delineation of prostheses in general or a specific prosthesis.Prosthesis Failure: Malfunction of implantation shunts, valves, etc., and prosthesis loosening, migration, and breaking.Aortic Valve Insufficiency: Pathological condition characterized by the backflow of blood from the ASCENDING AORTA back into the LEFT VENTRICLE, leading to regurgitation. It is caused by diseases of the AORTIC VALVE or its surrounding tissue (aortic root).Prosthesis Fitting: The fitting and adjusting of artificial parts of the body. (From Stedman's, 26th ed)Reoperation: A repeat operation for the same condition in the same patient due to disease progression or recurrence, or as followup to failed previous surgery.Heart Valve Diseases: Pathological conditions involving any of the various HEART VALVES and the associated structures (PAPILLARY MUSCLES and CHORDAE TENDINEAE).Anatomic Landmarks: Reference points located by visual inspection, palpation, or computer assistance, that are useful in localizing structures on or within the human body.Mitral Valve: The valve between the left atrium and left ventricle of the heart.Device Removal: Removal of an implanted therapeutic or prosthetic device.Abortion, Septic: Any type of abortion, induced or spontaneous, that is associated with infection of the UTERUS and its appendages. It is characterized by FEVER, uterine tenderness, and foul discharge.Tricuspid Valve: The valve consisting of three cusps situated between the right atrium and right ventricle of the heart.Pericardium: A conical fibro-serous sac surrounding the HEART and the roots of the great vessels (AORTA; VENAE CAVAE; PULMONARY ARTERY). Pericardium consists of two sacs: the outer fibrous pericardium and the inner serous pericardium. The latter consists of an outer parietal layer facing the fibrous pericardium, and an inner visceral layer (epicardium) resting next to the heart, and a pericardial cavity between these two layers.Cardiac Catheterization: Procedures in which placement of CARDIAC CATHETERS is performed for therapeutic or diagnostic procedures.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Tricuspid Valve Insufficiency: Backflow of blood from the RIGHT VENTRICLE into the RIGHT ATRIUM due to imperfect closure of the TRICUSPID VALVE.Calcinosis: Pathologic deposition of calcium salts in tissues.Echocardiography, Transesophageal: Ultrasonic recording of the size, motion, and composition of the heart and surrounding tissues using a transducer placed in the esophagus.Endocarditis, Bacterial: Inflammation of the ENDOCARDIUM caused by BACTERIA that entered the bloodstream. The strains of bacteria vary with predisposing factors, such as CONGENITAL HEART DEFECTS; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; or intravenous drug use.Postoperative Complications: Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.Mitral Valve Insufficiency: Backflow of blood from the LEFT VENTRICLE into the LEFT ATRIUM due to imperfect closure of the MITRAL VALVE. This can lead to mitral valve regurgitation.Echocardiography, Three-Dimensional: Echocardiography amplified by the addition of depth to the conventional two-dimensional ECHOCARDIOGRAPHY visualizing only the length and width of the heart. Three-dimensional ultrasound imaging was first described in 1961 but its application to echocardiography did not take place until 1974. (Mayo Clin Proc 1993;68:221-40)Prosthesis-Related Infections: Infections resulting from the implantation of prosthetic devices. The infections may be acquired from intraoperative contamination (early) or hematogenously acquired from other sites (late).Time Factors: Elements of limited time intervals, contributing to particular results or situations.Thromboembolism: Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.Hospital Mortality: A vital statistic measuring or recording the rate of death from any cause in hospitalized populations.Hemodynamics: The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM.ElastinGlutaral: One of the protein CROSS-LINKING REAGENTS that is used as a disinfectant for sterilization of heat-sensitive equipment and as a laboratory reagent, especially as a fixative.Illusions: The misinterpretation of a real external, sensory experience.Patents as Topic: Exclusive legal rights or privileges applied to inventions, plants, etc.Carcinoid Heart Disease: Cardiac manifestation of gastrointestinal CARCINOID TUMOR that metastasizes to the liver. Substances secreted by the tumor cells, including SEROTONIN, promote fibrous plaque formation in ENDOCARDIUM and its underlying layers. These deposits cause distortion of the TRICUSPID VALVE and the PULMONARY VALVE eventually leading to STENOSIS and valve regurgitation.Pulmonary Valve Insufficiency: Backflow of blood from the PULMONARY ARTERY into the RIGHT VENTRICLE due to imperfect closure of the PULMONARY VALVE.Pulmonary Valve: A valve situated at the entrance to the pulmonary trunk from the right ventricle.Heart Murmurs: Heart sounds caused by vibrations resulting from the flow of blood through the heart. Heart murmurs can be examined by HEART AUSCULTATION, and analyzed by their intensity (6 grades), duration, timing (systolic, diastolic, or continuous), location, transmission, and quality (musical, vibratory, blowing, etc).

Destructive aortic valve endocarditis from Brucella abortus: survival with emergency aortic valve replacement. (1/643)

Brucella abortus infection of the aortic valve caused acute aortic regurgitation leading to severe left ventricular failure in a 62-year-old man. He made an excellent recovery after emergency aortic valve replacement. This is the third reported case of successful heart valve replacement for Brucella endocarditis and the second such case involving the aortic valve.  (+info)

Long-term survival and valve-related complications in young women with cardiac valve replacements. (2/643)

BACKGROUND: The type of cardiac valve replacement associated with the lowest health risks for young women who may undergo pregnancies is unknown. We investigated which valve type was associated with greatest patient and valve survival and the effect of pregnancy on valve loss. METHODS AND RESULTS: In this retrospective study, all women 12 to 35 years old who underwent valve replacements between 1972 and 1992 at Greenlane Hospital were identified, and follow-up was available in 93%. The 232 women were followed up for 1499 patient-years. Ten-year survival of women with mechanical (n=178), bioprosthetic (n=73), and homograft (n=72) valves was 70% (95% CI, 59% to 83%), 84% (95% CI, 72% to 99%), and 96% (95% CI, 91% to 100%), P=0.002. After adjustment for confounding variables, the relative risk (RR) of death with mechanical compared with bioprosthetic valves was 2.17 (95% CI, 0.78 to 5.88). Thromboembolic events occurred in 45% of women with mechanical valves within 5 years, compared with 13% with bioprosthetic valves, P=0.0001. Valve loss at 10 years was higher in bioprosthetic valves [82% (95% CI, 62% to 92%)] than in mechanical [29% (95% CI, 17% to 39%)] or homograft [28% (95% CI, 12% to 41%)] valves, P=0.0001. Pregnancy was not associated with increased bioprosthetic (RR, 0.96; 95% CI, 0.68 to 1. 35), homograft (RR, 0.65; 95% CI, 0.37 to 1.13), or mechanical (RR, 0.54; 95% CI, 0.27 to 1.08) valve loss. CONCLUSIONS: Although 10-year valve survival was greater with mechanical than bioprosthetic valves, mechanical valves may be associated with reduced patient survival in young women. Thromboembolic complications, often with long-term sequelae, were common with mechanical valves. Pregnancy did not increase structural deterioration or reduce survival of bioprosthetic valves.  (+info)

Haemodynamic performance of aortic pericardial bioprostheses and bileaflet prostheses at rest and during exercise: implications for the surgical management of patients with small aortic roots. (3/643)

OBJECTIVE: To determine the haemodynamic behaviour, at rest and during exercise, of aortic valve pericardial bioprostheses and different sizes of bileaflet prosthesis. DESIGN: Observational study. SETTING: Tertiary medical centre. PATIENTS AND INTERVENTIONS: 74 patients (33 women, 41 men; mean age 64 years) in whom 40 pericardial bioprostheses and 34 bileaflet prostheses sized 19, 21, or 23 mm had been implanted to replace aortic valves. MAIN OUTCOME MEASURES: Doppler echocardiography at rest and at peak exercise, between 12 and 47 months after surgery. RESULTS: All patients achieved a significant increase in heart rate, systolic blood pressure, and cardiac output with exercise. Transvalvar pressure fall, valve area, and left ventricular systolic and diastolic function indices also underwent significant changes with exercise. Reductions in peak and mean transvalvar pressure, at rest and at peak exercise, were greater in patients with small valves (p < 0.05). Valve areas and effective area index were greater in the patients with larger valves (p < 0.001). There were no significant differences between patients with mechanical and biological prostheses with regard to transvalvar pressure fall and valve areas at rest and at peak exercise. CONCLUSIONS: 19 mm and 21 mm aortic prostheses and bioprostheses continue to create significant obstruction, particularly with exercise.  (+info)

The use of a stentless porcine bioprosthesis to repair an ascending aortic aneurysm in combination with aortic valve regurgitation. (4/643)

Over the years, many surgical methods have evolved for the treatment of ascending aortic aneurysm in combination with aortic valve regurgitation; however, precise guidelines for optimal surgical techniques for varying presentations have not been defined. We describe the use of a stentless porcine bioprosthesis (Medtronic Freestyle) in a patient with an ascending aortic aneurysm and aortic regurgitation. We used the complete root replacement method, and anastomosed a Dacron graft (Hemashield) between the bioprosthetic valve and the native aorta to replace the distal part of the aneurysm.  (+info)

Hemodynamic and physical performance during maximal exercise in patients with an aortic bioprosthetic valve: comparison of stentless versus stented bioprostheses. (5/643)

OBJECTIVES: The objective of this study was to compare stentless bioprostheses with stented bioprostheses with regard to their hemodynamic behavior during exercise. BACKGROUND: Stentless aortic bioprostheses have better hemodynamic performances at rest than stented bioprostheses, but very few comparisons were performed during exercise. METHODS: Thirty-eight patients with normally functioning stentless (n = 19) or stented (n = 19) bioprostheses were submitted to a maximal ramp upright bicycle exercise test. Valve effective orifice area and mean transvalvular pressure gradient at rest and during peak exercise were successfully measured using Doppler echocardiography in 30 of the 38 patients. RESULTS: At peak exercise, the mean gradient increased significantly less in stentless than in stented bioprostheses (+5 +/- 3 vs. +12 +/- 8 mm Hg; p = 0.002) despite similar increases in mean flow rates (+137 +/- 58 vs. +125 +/- 65 ml/s; p = 0.58); valve area also increased but with no significant difference between groups. Despite this hemodynamic difference, exercise capacity was not significantly different, but left ventricular (LV) mass and function were closer to normal in stentless bioprostheses. Overall, there was a strong inverse relation between the mean gradient during peak exercise and the indexed valve area at rest (r = 0.90). CONCLUSIONS: Hemodynamics during exercise are better in stentless than stented bioprostheses due to the larger resting indexed valve area of stentless bioprostheses. This is associated with beneficial effects with regard to LV mass and function. The relation found between the resting indexed valve area and the gradient during exercise can be used to project the hemodynamic behavior of these bioprostheses at the time of operation. It should thus be useful to select the optimal prosthesis given the patient's body surface area and level of physical activity.  (+info)

Valve replacement for aortic stenosis in patients with poor left ventricular function: comparison of early changes with stented and stentless valves. (6/643)

BACKGROUND: Long-standing aortic stenosis causes significant left ventricular (LV) dysfunction, which may progress irreversibly. In many cases, LV function can be salvaged by aortic valve surgery, although debate exists regarding the best valve prosthesis to use. METHODS AND RESULTS: We studied 33 patients retrospectively who had significant aortic stenosis and impaired LV systolic function, as assessed by transthoracic Doppler echocardiography. Patients were assessed preoperatively and before discharge from the hospital. A total of 20 patients received a stentless (homograft or Toronto) valve, and 13, a stented valve. No patient had significant aortic regurgitation or other valvular disease. Preoperatively, fractional shortening was 18.8+/-5.5% in the stentless group and 18.6+/-3.8% in the stented group. Postoperatively, it was 25.6+/-6.9% (P<0.001 compared with baseline) and 17.0+/-2.8%, respectively (P<0.001 compared with stentless group). Fractional shortening improved because of a reduction in LV end-systolic and end-diastolic dimensions in the stentless group. Systolic long axis function at the LV free wall also recovered, with an increase in systolic excursion and both peak shortening and lengthening rates. No change was noted in mitral valve Doppler patterns. CONCLUSIONS: Patients who received a stentless valve demonstrated a significantly greater early improvement in LV systolic function compared with those who received a stented valve.  (+info)

Prospectively randomized evaluation of stentless versus conventional biological aortic valves: impact on early regression of left ventricular hypertrophy. (7/643)

BACKGROUND: The aim of this prospectively randomized study was to evaluate left ventricular hypertrophy and its regression after stentless versus conventional biological aortic valve replacement. METHODS AND RESULTS: From March 1996 through April 1998, 180 patients were prospectively selected; 106 patients received a stentless aortic valve (SAV), and 74 received a conventional stented bioprosthesis (CSB). Of these patients, 95% and 96%, respectively, had aortic stenosis. Their mean age was 72.3 and 74.8 years, and there were no significant differences in left ventricular function, preoperative pressure gradients, and NYHA functional status. Aortic annulus diameter indexes were comparable at 13.46 (SAV) versus 13.55 (CSB) mm (P=NS). Larger SAVs were implanted because of the oversizing technique. In-hospital mortality (n=3 and 1 for SAV and CSB) was not valve related. At follow-up, all patients were in NYHA class 1 or 2. Baseline end-diastolic left ventricular posterior wall thickness was 15.6 (SAV) and 14.8(CSB) mm (P=NS) and decreased to 11. 8 (SAV) and 13.2 (CSB) mm (P<0.05) at 6 months. Left ventricular mass index was 213 and 202 g/m(2) at baseline (P=NS), whereas after 6 months, it was 141 (SAV) and 170 (CSB) g/m(2) (P<0.05). CONCLUSIONS: Regression of left ventricular hypertrophy occurs in all patients after aortic valve replacement but is significantly enhanced after SAV implantation. This possibly is due to improved transvalvular hemodynamics.  (+info)

Mid-term comparative follow-up after aortic valve replacement with Carpentier-Edwards and Pericarbon pericardial prostheses. (8/643)

BACKGROUND: The first generation of pericardial valves had a high rate of premature deterioration. The aim of this study was to compare the outcome after aortic valve replacement with second generation pericardial prostheses (Pericarbon and Carpentier-Edwards). METHODS AND RESULTS: Between 1987 and 1994, 162 patients underwent aortic valve replacement with either a Pericarbon (n=81, 69+/-11 years) or a Carpentier-Edwards (n=81, 70+/-11 years) pericardial prosthesis. Mean follow-up was 4.4+/-2.7 years for Pericarbon and 4.8+/-2.4 years for Carpentier-Edwards valves (P=0. 27), giving a total follow-up of 745 patient-years. Thirty-day mortality and 5-year actuarial survival were, respectively, 6.2% and 63.2+/-5.7% in the Pericarbon group and 6.2% and 63.5+/-5.6% in the Carpentier-Edwards group. At 8 years, freedom from (and linearized rates per patient-year) thromboembolism, structural failure, and all valve-related events were, respectively, 91.8+/-3.6% (1.4%), 76. 9+/-8.7% (2.5%), and 58.4+/-9.3% (5.6%) in the Pericarbon group and 94.4+/-2.7% (1%), 100% (0%, P<0.01), and 88.8+/-3.7% (2%, P<0.05) in the Carpentier-Edwards group. There were 9 (11.1%) Pericarbon structural failures related predominantly to severe calcification and stenosis. The actual reoperation rate was 7.4% (1.6% per patient-year) in the Pericarbon group for fibrocalcific degeneration (n=3), periprosthetic leak (n=1), endocarditis (n=1), and aortic dissection (n=1). There was neither structural valve failure nor valve reoperation in the Carpentier-Edwards group. Echocardiographic review of 70 patients from 85 survivors (82.3%) found 4 additional Pericarbon valves with signs of early structural failure but no Carpentier-Edwards valve with such changes. CONCLUSIONS: Eight years after aortic valve replacement, Pericarbon pericardial prostheses compared unfavorably with Carpentier-Edwards pericardial prostheses, with a high incidence of structural valve failure and reoperation.  (+info)

TY - JOUR. T1 - Hemodynamic evaluation of 19-mm Carpentier-Edwards pericardial bioprosthesis in aortic position. AU - Takakura, Hiromitsu. AU - Sasaki, Tatsuumi. AU - Hashimoto, Kazuhiro. AU - Hachiya, Takashi. AU - Onoguchi, Katsuhisa. AU - Oshiumi, Motohiro. AU - Takeuchi, Shigeyuki. PY - 2001. Y1 - 2001. N2 - Background. The aortic Carpentier-Edwards pericardial bioprosthesis offers good long-term clinical outcomes with a low rate of structural deterioration. However, little in vivo hemodynamic data is available for this bioprosthesis. Methods. To determine the hemodynamic performance of the 19-mm Carpentier-Edwards pericardial valve, both cardiac catheterization and dobutamine stress echocardiography were electively performed in 10 patients. The mean age at the study was 71.6 ± 4.4 years and the mean body surface area was 1.39 ± 0.11 m2. The peak-to-peak gradient, instantaneous peak gradient, mean gradient, and valve orifice area were measured by standard cardiac catheterization. The ...
Transcatheter aortic valve implantation for failing surgical aortic bioprosthetic valve: from concept to clinical application and evaluation (part 2). JACC Cardiovasc Interv. 2011 Jul; 4(7):733-42 ...
We describe a case of a 76-year old male who presented with progressive dyspnoea. He underwent an aortic valve replacement with a Freedom SOLO bioprosthesis 6 years ago. Transthoracic echocardiography showed a moderate-to-severe leakage of the Freedom SOLO bioprosthesis. During surgical reintervention, a partial tear of the left coronary cusp was seen from the commissure of the right coronary cusp to its base. After radiographic and microscopic examination, no clear cause was found for the failure of this Freedom SOLO bioprosthesis. To our knowledge, this is the third failure of a Freedom SOLO bioprosthesis reported in the literature. When the long-term follow-up of the Freedom SOLO bioprosthesis is available, it has to be compared with other bioprosthesis for long-term durability. ...
TY - JOUR. T1 - Aortic Valve Bioprostheses. T2 - Leaflet Immobility and Valve Thrombosis. AU - Holmes, David. AU - Mack, Michael J.. PY - 2017/5/2. Y1 - 2017/5/2. N2 - Leaflet immobility and valve thrombosis have been reported with both transcatheter and surgical aortic valve bioprostheses. The relationships between these abnormalities and their incidence, time course, clinical significance, predisposing factors, optimal imaging modality, and current therapeutic options remain uncertain but are rapidly evolving. Four-dimensional computerized tomographic imaging has been determined to have the highest sensitivity in studies evaluating leaflet immobility and valve thrombosis. Echocardiography is also used during surveillance, but it appears to be less sensitive. The definitive diagnosis of valve thrombosis is based on a combination of diagnostic 4-dimensional computerized tomographic imaging findings, resolution of imaging abnormalities, and elevated transcatheter gradients with anticoagulation or ...
Title:Prevention of Bioprosthetic Heart Valve Calcification: Strategies and Outcomes. VOLUME: 21 ISSUE: 22. Author(s):L.P. Bre, R. McCarthy and W. Wang. Affiliation:Network of Excellence for Functional Biomaterials (NFB), National University of Ireland, Galway, IDA Business Park, Dangan, Galway, Ireland.. Keywords:Anticalcification, bioprosthesis, crosslinking, glutaraldehyde, heart valve replacement, mineralization.. Abstract:Despite the significant advances in cardiac surgery, heart valve replacement still faces a dilemma. While mechanical valves offer lifelong durability they also commit patients to anticoagulation treatment for the rest of their life. On the other hand, bioprosthetic valves have superior hemodynamic performance but durability of the bioprosthesis limits their use to the elderly, with early onset calcification being the primary cause of biomaterial breakdown. Considering that bioprosthetic valves are not reliant upon anticoagulation, there has been much focus on measures to ...
There has been a trend toward more frequent use of bioprosthetic valves, especially in the young generations, over the last decade.1,2 According to the Society of Thoracic Surgeons database, use of bioprosthetic valve increased from 44% in 1996 to 78% in 2006 in North America.1 Freedom from warfarin use and restrictions on diet and activities make bioprosthetic valves more attractive and popular, and multiple reports have shown that choosing a bioprosthetic valve does not decrease survival despite the increased rate of reoperation.3,4. Article see p 2012. The Mitroflow aortic prosthesis (Sorin Group Inc) is one of the most frequently used bioprostheses, with ,100 000 implanted worldwide.5 The bovine pericardium is mounted externally around the stent, which maximizes the flow relative to the stent size. The valve is placed in the supra-annular position compared with the intra-annular position in some of the other bioprostheses. These characteristics allow superior valve hemodynamics in the ...
Several studies have recognized the high prognostic relevance of achieving an optimal hemodynamic result after aortic valve replacement (1-3,13-16). The presence of severe PPM has been associated with lesser improvement in the functional capacity of the patients (13), lesser regression of LV hypertrophy (14), higher rates of cardiac failure (16), and higher rates of perioperative and long-term mortality (2,3,15,16) after SAVR. The Magna and Freestyle valves are among the most commonly used stented and stentless bioprostheses for SAVR, and the results of valve hemodynamic performance observed in the present study for these 2 types of bioprosthesis were consistent with those of previous studies (17-20), although the aortic annulus and bioprosthesis size were smaller in the present study. Previous studies have also reported that the hemodynamic performance of stentless bioprostheses is generally superior, and accordingly, the prevalence/severity of PPM is lower compared with stented bioprostheses ...
Calcification of glutaraldehyde-preserved bioprosthetic cardiac valves represents a serious clinical problem. Previous work from this laboratory has established the presence in clinical bioprosthetic valve calcifications of vitamin K-dependent calciu
Since the first implant in September 1982, the Medtronic Hancock® II has provided more than 20 years of excellent hemodynamic performance and durability. Design improvements over the past generations include: low profile, flexible stent, Supra-X™ supra-annular placement, T6 anti-calcification tissue treatment, modified fixation process, CINCH® advanced implant system and ULTRA™ minimized sewing ring. Valve sizing is a critical consideration in obtaining optimal hemodynamic performance. This is particular true in small aortic roots. A critical issue is the size of the prosthesis in relation to the patients annulus.. The objective of this clinical study is to evaluate, at six and twelve months, the hemodynamic performance of the HancockÒ Ultra™ bioprosthesis in the aortic position, to analyze the incidence of patient prosthesis mismatch, correlation of gradients, and to ascertain frequency at which a larger valve size is used vs. a patients debrided annulus diameter. ...
Health,...MINNEAPOLIS Nov. 24 /- ATS Medical Inc.(Nas... (Logo: a href http://www.newscom.com/cgi-bin/prnh/20040202/ATSI... The ATS 3f Aortic Bioprosthesis is the Companys first entry into ... The ATS 3f Aortic Bioprosthesis is the only tissue valve that pre...,ATS,Medical,Announces,First,Commercial,Implants,of,the,ATS,3f,Aortic,Bioprosthesis,in,the,United,States,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
Between May 1st 1985 and December 31st 1992, 283 Carpentier-Edwards pericardial valves were implanted in 260 patients in the aortic (n = 196), mitral (n = 41) and both aortic and mitral (n = 23) positions at the Gasthuisberg University Hospital in Leuven, Belgium. Patients undergoing tricuspid valve replacement or mixed replacement with another type of prosthesis were excluded from this study. The mean age was 70 +/- 7 years, there were 121 males and 139 females. The mean follow up was 40.55 months, the total follow up experience 10543 months (878.6 patients years). Hospital mortality was 10.4%, and was not significantly related to the position of the valve: 17.3% +/- 7.88% (n = 23) for double valve replacement, 10.2% +/- 2.16% (n = 196) for aortic valve replacement and 7.3% +/- 4.06% (n = 41) for mitral valve replacement. Hospital mortality was 14.1% +/- 3.27% for those with and 7.48% +/- 2.5% for those without concomitant coronary surgery (p = NS). Survival at 92 months was 63% +/- 6% and was ...
A bioprosthetic heart valve comprising leaflets with free edges which do not impinge on adjacent leaflets when the leaflets are closed before being implanted and subject to body fluids and cardiac pressure cycles. Commissures supporting the leaflets have semi-permeable membranes which reduce the pressure load on the leaflets during implantation. In response to immersion in body fluids, the membranes become substantially impermeable. The leaflets can stretch in response to loads and hydration, so that the free edges mate shortly after implantation. First and second mechanisms for supporting leaflets to provide multiple effective spring constants. An inner frame supporting commissures of the valve is elastic, permitting the commissures to bend in toward the center of the prosthetic heart valve at very low loads. A relatively rigid annular support ring supports the elastic frame and provides the second spring constant mechanism. The leaflets have an uncoupled mating edge where the leaflet approach each
Transcatheter heart valve in valve implantation with Edwards SAPIEN bioprosthetic valve for different degenerated bioprosthetic valve positions (First Iranian ViV report with mid-term follow up) ...
A packaging system is disclosed for shipping a prosthetic tissue valve in a storage solution and preparing and loading of the bioprosthetic valve onto a catheter-based delivery system. The packaging system includes a fluid tight container filled with the storage solution attached to a delivery catheter, wherein the container surrounds the prosthetic tissue valve that is in a pre-loaded position on the delivery catheter during shipment and storage. The prosthetic tissue valve may include an attachment mechanism that attaches to the delivery catheter to properly position the tissue valve for loading within the delivery catheter. In another embodiment where the prosthetic tissue valve is not attached to the delivery catheter during shipment, the attachment mechanism may interact with the prosthetic tissue valve shipping container to prevent the bioprosthetic valve from moving during shipment.
Bioprosthetic valve thrombosis (BPVT) can occur several years after implantation but much earlier than degeneration, stress Sorin V. Pislaru, MD, PhD, and colleagues. The good news, they say, is that cases-once diagnosed-respond well to vitamin K antagonist (VKA) therapy.. The findings are being published in the December 1, 2015, issue of the Journal of the American College of Cardiology.. Raj R. Makkar, MD, of Cedars-Sinai Heart Institute (Los Angeles, CA), lead author of the NEJM paper, told TCTMD in a telephone interview: Clearly weve underappreciated the importance of leaflet thrombosis on structural valve failure, and in a subset of patients this may be the mechanism.. No prospective RCTs have tested the value of anticoagulation in patients with bioprosthetic valves, and studies on both surgical and transcatheter valves would be important, he noted.. Makkar said awareness of these issues is growing in the TAVR field. I think people are serious and people are interested. Everybody ...
TY - JOUR. T1 - Morphological comparison of mitral and aortic bioprostheses explanted from the same patient for primary tissue failure. AU - Pansini, S.. AU - Di Summa, M.. AU - Galloni, M.. AU - Gagliardotto, P.. AU - Parisi, F.. AU - Zattera, G.. AU - Punta, G.. AU - Girotto, M.. AU - Cesarani, F.. PY - 1996/6. Y1 - 1996/6. N2 - Host factors might influence the fate of tissue prostheses. We have analyzed the tissue failure phenomenon in mitral and aortic porcine bioprostheses explanted from the same patient so as to avoid the bias of host factors. The 50 bioprostheses of this study were explanted from 25 patients reoperated on because of malfunctioning due to primary tissue failure. Bioprostheses explanted were photographed, radiographed and observed in polarizing light. All lesions analyzed received a score on the basis of morphological criteria. No difference was observed in the occurrence of pannus, tears or cells infiltrates. Calcifications occurred more extensively in mitral position (p = ...
The VIV procedure is technically demanding and should be reserved for highly experienced centers. Operators should be skilled in the handling of device malposition, retrieval techniques, and implantation of a second TAVR device, if needed. During screening, the Heart Team must have all of the information about and be familiar with the particular characteristics of the surgical bioprosthesis: the mode of degeneration and echocardiographic parameters (isolated paravalvular regurgitation should be excluded); valve size (most importantly, bioprosthesis internal diameter should be used for TAVR device and size selection; because of better hemodynamic results, CoreValve may be preferred in cases of small bioprosthesis with internal diameter ,20 mm); valve position (intra-annular versus supra-annular); valve type (stented versus stentless); the relation of the bioprosthetic valve to its radio-opaque markers; and the risk for coronary obstruction when VIV is performed inside that specific ...
The valve-in-valve concept is an emerging therapeutic option for patients with degenerative failure of previously implanted xenografts. Reoperation of degenerated bioprostheses has a high mortality risk that increases with the age and associated comorbidities of the patients. The transcatheter valve-in-valve implantation does not need resternotomy or cardiopulmonary bypass, potentially reducing the morbidity and mortality risk. However, unlike the transcatheter implants in native valves, in the valve-in-valve procedures, the leaflets and calcified annulus are replaced with the rigid annulus of the xenograft. This requires accurate sizing of the transcatheter valve, currently available in 2 sizes. Therefore, 3-dimensional imaging techniques, particularly multi-detector row computed tomography (MDCT), may provide a more exact sizing of the host xenograft ring. We report a mitral valve-in-valve procedure in a 79-year-old female patient with previous aortic and mitral valve replacement (a 21-mm and ...
TY - JOUR. T1 - Long-Term Outcomes of Anticoagulation for Bioprosthetic Valve Thrombosis. AU - Petrescu, Ioana. AU - Egbe, Alexander C.. AU - Ionescu, Filip. AU - Nkomo, Vuyisile T.. AU - Greason, Kevin L.. AU - Pislaru, Cristina. AU - Pellikka, Patricia A.. AU - Connolly, Heidi M.. AU - Pislaru, Sorin V.. PY - 2020/3/3. Y1 - 2020/3/3. N2 - Background: Early in the prevention and treatment of bioprosthetic valve thrombosis (BPVT), anticoagulation is effective, but the long-term outcome after BPVT is unknown. Objectives: The goal of this study was to assess the long-term outcomes of patients with BPVT treated with anticoagulation. Methods: This analysis was a matched cohort study of patients treated with warfarin for suspected BPVT at the Mayo Clinic between 1999 and 2017. Results: A total of 83 patients treated with warfarin for suspected BPVT (age 57 ± 18 years; 45 men [54%]) were matched to 166 control subjects; matching was performed according to age, sex, year of implantation, and ...
A new study has found that in patients with failed bioprosthetic aortic valves who underwent transcatheter valve-in-valve implantation, the survival rate was only 83 percent
Bioprosthetic valves are increasingly used in preference to mechanical valves in open SAVR, as lifelong oral anticoagulation is not required and its attendant complications can be avoided. A recent study has shown similar long-term survival rates in patients with bioprosthetic and mechanical valves. However, patients with bioprosthetic valves require reoperations due to their limited durability and expected degeneration;(12) those undergoing such reoperations face increased surgical risk due to their more advanced age (compared with their age during the index SAVR) during the redo surgery and scarring in the non-virgin chest. Consequently, valve-in-valve TAVI appears to be an attractive, minimally invasive method of replacing the degenerated surgical aortic bioprosthesis without the need for a reoperation. Several small case series and a global registry have shown that it is a feasible and viable option for patients at high risk.(5-9). In our initial Asian experience of valve-in-valve TAVI in ...
Fingerprint Dive into the research topics of Comparative performance of transcatheter aortic valve-in-valve implantation versus conventional surgical redo aortic valve replacement in patients with degenerated aortic valve bioprostheses: systematic review and meta-analysis. Together they form a unique fingerprint. ...
Methods and results Preoperative echocardiography and dobutamine stress echocardiography at 1 year postoperatively were undertaken in 106 patients (n=18-24 from each group). Stentless bioprostheses, whether porcine or bovine, displayed superior haemodynamics across nearly all echocardiographic parameters: lower gradients, larger effective orifice area, higher dimensionless severity index (DSI) and lower resistance, when compared with stented or mechanical prostheses. Comparing both stented designs, bovine tissue performed the worst at rest, but with stress, there was no difference. The stress performances of the stentless bioprostheses were similar to the mildly stenosed native aortic valve, whereas the performances of the stented and mechanical prostheses resembled that of native valves with mild-to-moderate stenoses. Haemodynamic differences, however, did not translate into differences in left ventricular mass reduction at 1 year.. ...
Sorin Group (Milan, Italy) has been awarded CE mark approval for the Solo Smart, a stentless aortic valve implant. Like its predecessor, the Freedom Solo v
CARDIOTHORACIC ANESTHESIOLOGY: Clinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Aortic Valves by Four-Dimensional Computed Tomography is organized by The Society of Thoracic Surgeons (STS).
Surgical Bailout Therapy after Implantation of a Medtronic CoreValve Bioprosthesis. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
When facing heart valve replacement surgery, its important to understand the available options. Check out this blog post to learn more!
A biomaterial useful for bioprostheses such as bioprosthetic heart valves is provided in which the fixed tissue has improved elastic properties. The high elastin-containing biomaterial is further characterized by having anisotropic properties wherein the biological material has a greater stiffness in one direction and a greater elasticity in a cross direction. For instance, the biological material has an elastin content of about 30% by weight. In one embodiment, the biological material is vena cava tissue.
Results In patients with VHD, rivaroxaban was associated with more ICH and major bleeding than other NOACs, while edoxaban 30 mg was associated with least major bleeding. Data combining all NOACs showed a significant reduction in SSE, MI and ICH (0.70, [0.57 to 0.85; p,0.001]; 0.70 [0.50 to 0.99; p,0.002]; and 0.46 [0.24 to 0.86; p,0.01], respectively). Analysis of 280 patients with AF and a BPHV showed similar outcomes with NOACs and warfarin. ...
Disclosed is a controlled autolysis method for making biological tissue substantially acellular by exposing the biological material, prior to any fixation thereof, to at least one buffered solution having a pH in the range from about 5.0 to 8.0 and a temperature in the range from about 12 C. to 30 C. for a sufficient period of time to render at least one region of the biological material substantially acellular while substantially preserving the structural integrity and non-cellular structural components of the biological material. Also disclosed is a method of making a bioprosthetic heart valve using biological material that has been treated by controlled autolysis and a method of treating a mammal having a defective heart valve using a bioprosthetic heart valve made, in part, by controlled autolysis.
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Mayos structural heart team provides comprehensive care to patients who have previously undergone surgery to replace the mitral or tricuspid valve with a tissue bioprosthesis. Existing dysfunctional bioprosthetic valves can be
Brief summary: aortic bioprostheses. Indications: For use in patients whose aortic valvular disease warrants replacement of their natural or previously placed prosthetic valve.. Contraindications: Do not use if surgeon believes it would be contrary to the patients best interests.. Complications and side effects: Stenosis, regurgitation, endocarditis, hemolysis, thromboembolism, valve thrombosis, nonstructural dysfunction, structural valve deterioration, anemia, arrhythmia, hemorrhage, transient ischemic attack/stroke, congestive heart failure, myocardial infarction, angina, any of which could lead to reoperation, explantation, permanent disability, and death.. Warnings: Alternative therapies should be considered in the presence of conditions affecting calcium metabolism or when calcium containing chronic drug therapies are used, including children, adolescents, young adults, and patients on a high calcium diet or maintenance hemodialysis. Should be used with caution in the presence of severe ...
November 27, 2007 - St. Jude Medical Inc. announced FDA approval of its Epic Stented Tissue Valve with Linx AC Technology. The Epic Valve, which is identical in design to the companys Biocor Valve, also incorporates patented anti-calcification technology designed to protect against tissue mineralization, or hardening.. An estimated 100,000 Americans undergo heart valve replacement annually and the majority of them receive tissue valves. Valve durability is affected by both mechanical stress and tissue calcification. The Epic Valve is designed to address both issues to deliver long-term performance.. The Epic Valve sets a new standard for addressing tissue mineralization and potentially extending long-term valve durability, said Vibhu Kshettry, M.D., director of Cardiac Surgery at the Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, and a principal investigator in the Epic clinical study. Enhanced durability, combined with a design that facilitates the implant ...
OBJECTIVES: The aim of this study was to evaluate the hemodynamic performance of a sutureless bioprosthesis under high workload at mid-term follow-up. METHODS: Thirty-two patients who underwent isolated aortic valve replacement with a Perceval sutureless bioprosthesis with a minimum follow-up of 1 year were enrolled in this study. S size prosthesis was deployed in 10 patients (31.3%), M size in 9 (28.1%), L size in 8 (25%) and XL size in 5 (15.6%). Effective orifice area (EOA), EOA index (EOAi), and transvalvular gradients were assessed at rest and during dobutamine stress echocardiography (DSE) a median of 19 ...
A system for treating a vascular condition includes a conduit having an inner wall and at least one locking member positioned within the inner wall of the conduit. The system also includes a stented valve positioned in contact with the locking member within the inner wall of the conduit. A method for treating a vascular condition includes inserting a conduit with a stented valve into a target region of a vessel, positioning a contact portion of the stented valve against a locking portion of the conduit and preventing migration of the stented valve within the conduit based on the positioning.
A system for treating a vascular condition includes a conduit having an inner wall and at least one locking member positioned within the inner wall of the conduit. The system also includes a stented valve positioned in contact with the locking member within the inner wall of the conduit. A method for treating a vascular condition includes inserting a conduit with a stented valve into a target region of a vessel, positioning a contact portion of the stented valve against a locking portion of the conduit and preventing migration of the stented valve within the conduit based on the positioning.
Diagnosis Code T82.223S information, including descriptions, synonyms, code edits, diagnostic related groups, ICD-9 conversion and references to the diseases index.
Continuous improvement in the mechanics, preservation and anticalcification treatment made bioprostheses the standard mode of valve replacement in the aging population. A novel Support System with large openings at the Commissural posts has been developed and the performance and durability of bioprostheses constructed went under evaluation. … Heart valve pulse duplicator. A heart valve pulse duplicator Vivitro SPS3891 (Vivitro Systems Inc., Victoria, BC Canada) was used to measure hemodynamic parameters. All tests were performed with the standard FDA waveform …. Go to the Article ...
Diagnosis Code T82.222S information, including descriptions, synonyms, code edits, diagnostic related groups, ICD-9 conversion and references to the diseases index.
Figure 2. Because of the surgical risk of a second thoracotomy, a logistic EuroSCORE of 7.14%, and associated comorbidity, a repeat operation was ruled out, and treatment by percutaneous implantation of a CoreValve aortic prosthesis was decided. The operation was successfully completed using local anesthesia and light sedation. A 29-mm CoreValve aortic prosthesis was implanted without complications through a femoral artery approach. The gradient peak disappeared (Figure 2B) and follow-up echocardiography showed perfect valve functioning (Figure 3A and B) with minimal regurgitation (Figure 3C). The patient was discharged 6 days after the procedure, with improved symptoms and a reduction of NTProBNP concentration from 2561.3 to 187.6 pg/ mL. At 8 months of follow-up, the patient was asymptomatic.. ...
We thank Dr. Vavuranakis and colleagues for their interest in our report of Post-implantation repositioning of the CoreValve percutaneous aortic valve (1) and for the opportunity to discuss our experience with repositioning techniques of the CoreValve prosthesis (Medtronic Inc., Minneapolis, Minnesota), which was beyond the scope of an Image in Intervention article. At the outset, we would like to state that the best repositioning technique for the CoreValve bioprosthesis is to aim at implanting the valve correctly the first time without having to reposition the valve later. In their letter, Dr. Vavuranakis et al. allude to an important point about implantation of the CoreValve bioprosthesis, which in our opinion is not sufficiently stressed. It has now become routine practice in our institution to post-dilate all CoreValve prostheses that have more than trivial (,1+) aortic regurgitation. In the majority of cases, this additional post-dilation optimizes expansion of the nitinol stent and ...
Early structural deterioration with the mitral Mitroflow pericardial valve requiring reoperation occurred in 6 patients. Clinical diagnosis of prosthetic failure was made 5 to 58 months after valve implantation (mean, 38 months). Re-replacement was c
Uma década adiante, emergindo do universo de Miles Davis, Herbie Hancock monta um grupo, o The Headhunters, com maiores aproximações à tradição popular afro-americana, de uma sonoridade bem mais acessível ao grande público e de grande sucesso. No álbum de título homônimo ao deste grupo, Head Hunters (1973), Hancock alterna bem sucedidas experimentações pelo eletrofunk com pitadas daquele espírito do quinteto de Miles. Sua discografia inclui discos voltados para o Jazz assim como algumas incursões pelo Fusion, Funk e Música Clássica. Poucos pianistas têm ou tiveram uma carreira tão fecunda quanto Hancock, que já atravessa algumas décadas como um dos maiores pianistas da história do Jazz. Gravou, em 1978, com Chick Corea um dos mais belos e surreais trabalhos de dupla ao piano: An Evening with Herbie Hancock & Chick Corea: In Concert. ...
The Europe bovine pericardial valve market is expected to reach US$ 1,229.57 million by 2027 from US$ 604.77 million in 2019. The market is estimated to grow at ...
The stent structure of the present invention would utilize an annular base ring defining an inflow orifice, with at least two circumferentially-spaced posts molded into the annular base ring at one end, and at their upper ends, molded into an upper ring comprising at least bi-segmented parabolic shaped scallops. The posts, which are constructed of spring steel molded in place, would provide the flextral capability necessary to allow relative movement between the scallops of the upper ring and the annular base. The parabolic-shaped segments taken together form a right cylinder of the inside diameter of the valve. The parabolic shape of the scallops reduce stress on the valve cusps.
TCTMD is produced by the Cardiovascular Research Foundation (CRF). CRF is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of their patients lives. For more information, visit http://www.crf.org.. ...
TY - JOUR. T1 - Bioprosthetic mitral valve thrombosis complicating antiphospholipid antibody syndrome, successfully treated with thrombolysis. AU - Chamsi-Pasha, Mohammed A.. AU - Alyousef, Tareq. AU - Sayyed, Samer H. PY - 2014/1/1. Y1 - 2014/1/1. N2 - The incidence of bioprosthetic valve thrombosis and related embolic complications is extremely rare, obviating the need for long-term anticoagulation. As a result, experience in the diagnosis and treatment of bioprosthetic valve thrombosis is fairly limited. We report the first case of antiphospholipid antibody syndrome presenting as bioprosthetic mitral valve thrombosis, 15 months after valve replacement, and successfully treated with thrombolytic therapy. (Echocardiography 2014;31:E278-E281).. AB - The incidence of bioprosthetic valve thrombosis and related embolic complications is extremely rare, obviating the need for long-term anticoagulation. As a result, experience in the diagnosis and treatment of bioprosthetic valve thrombosis is fairly ...
TY - JOUR. T1 - Detection, localization, and quantitation of bioprosthetic mitral valve regurgitation. An in vitro two-dimensional color-Doppler flow-mapping study. AU - Vandenberg, B. F.. AU - Dellsperger, K. C.. AU - Chandran, K. B.. AU - Kerber, R. E.. N1 - Copyright: Copyright 2018 Elsevier B.V., All rights reserved.. PY - 1988. Y1 - 1988. N2 - The usefulness of two-dimensional color-Doppler flow-imaging (2D Doppler) in the detection, localization, and quantitation of bioprosthetic mitral valve regurgitation is uncertain. Mitral bioprostheses, before and after the creation of transvalvular (n = 33), paravalvular (n = 17), or combined (n = 23) defects, were mounted in a pulsed duplication system (flow rates, 2.5-6.5 l/min; pulse rate, 70 beats/min). An Aloka 880 2D Doppler system (Japan) was used to image the regurgitant jets in the simulated left atrial chamber, analogous to images obtained with transesophageal echocardiography. Jet area was corrected to an estimate of stroke volume: 2D ...
The perfect heart valve substitute has not yet been developed and matching the patient to existing options to optimize survival and reduce valve-related complications remains challenging. The choices for aortic valve replacement (AVR) are mechanical valves, bioprosthetic valves, and biological valves such as aortic valve homograft and the Ross procedure (pulmonary autograft). The latter is a complex operation because it transfers the patients own pulmonary valve into the aortic position and uses a biological valve to replace the pulmonary valve, transforming a single-valve disease into a 2-valve disease. These considerations are not important to most North American patients who undergo AVR because they are older and the durability of bioprosthetic valves in this age group is excellent (1,2). The risk of bioprosthetic valve failure 20 years after AVR is ,10% in patients 70 years of age and older (1,2). A report based on the Society of Thoracic Surgeons Database from January 1997 to December 2006 ...
The Edwards SAPIEN 3 and SAPIEN 3 Ultra Transcatheter Heart Valve system is indicated for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a Heart Team, including a cardiac surgeon, to be appropriate for the transcatheter heart valve replacement therapy.. The Edwards SAPIEN 3 and SAPIEN 3 Ultra Transcatheter Heart Valve system is indicated for patients with symptomatic heart disease due to failing (stenosed, insufficient, or combined) of a surgical or transcatheter bioprosthetic aortic valve or surgical bioprosthetic mitral valve who are judged by a heart team, including a cardiac surgeon, to be at high or greater risk for open surgical therapy (i.e., predicted risk of surgical mortality ≥ 8% at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical co-morbidities unmeasured by the STS risk calculator).. Contraindications (Who should not use): ...
No survival difference was observed between use of mechanical and bioprosthetic mitral valves in patients aged 50-69 years matched by propensity score (actuarial 15-year survival 57.5% [95% confidence interval (CI) 50.5-64.4%] vs. 59.9% [95% CI 54.8-65.0%], hazard ratio [HR] 0.95 [95% CI 0.79-1.15]), or in a subgroup analysis of age by decade. Among patients matched by propensity score, mechanical versus bioprosthetic mitral valve replacement was associated with higher 15-year incidence of stroke (14.0% [95% CI 9.5-18.6%] vs. 6.8% [95% CI 4.5-8.8%], HR 1.62 [95% CI 1.10-2.39]) and bleeding events (14.9% [95% CI 11.0-18.8%] vs. 9.0% [95% CI 6.4-11.5%], HR 1.50 [95% CI 1.05-2.16]), but a lower incidence of reoperation (5.0% [95% CI 3.1-6.9%] vs. 11.1% [95% CI 7.6-14.6%], HR 0.59 [95% CI 0.37-0.94]).. ...
Subclinical leaflet thrombosis occurred frequently in bioprosthetic aortic valves, more commonly in transcatheter than in surgical valves. Anticoagulation (both NOACs and warfarin), but not dual antiplatelet therapy, was effective in prevention or treatment of subclinical leaflet thrombosis. Subclinical leaflet thrombosis was associated with increased rates of TIAs and strokes or TIAs. Despite excellent outcomes after TAVR with the new-generation valves, prevention and treatment of subclinical leaflet thrombosis might offer a potential opportunity for further improvement in valve haemodynamics and clinical outcomes.. ...
A method is provided for implanting a valve having at least one valve leaflet within the cardiovascular system of a subject. One step of the method includes preparing a substantially dehydrated bioprosthetic valve and then providing an expandable support member having oppositely disposed first and second ends and a main body portion extending between the ends. Next, the substantially dehydrated bioprosthetic valve is attached to the expandable support member so that the substantially dehydrated bioprosthetic valve is operably secured within the main body portion of the expandable support member. The expandable support member is then crimped into a compressed configuration and placed at a desired location within the cardiovascular system of the subject. Either before or after placement at the desired location, fluid or blood re-hydrates the substantially dehydrated bioprosthetic valve.
PhD Student Position in Mechanisms of Laminar-Turbulent Transition Past Bioprosthetic Aortic Valves The ARTORG Center for Biomedical Engineering Research is th
LivaNova PLC (NASDAQ:LIVN) a market-leading medical technology and innovation company, today announced that the advanced Perceval® Plus sutureless surgical aortic heart valve is now available for commercial release in Europe, having successfully completed a one-year limited launch with initial real-world clinical data gathering. Perceval Plus is positioned to become an essential component to any comprehensive heart program. Building on the clinically proven experience with Perceval®, this next-generation valve facilitates minimally invasive cardiac surgery (MICS) and makes sutureless aortic valve replacement available to a wide patient population. Key innovations with Perceval Plus include the anticalcification treatment, FREE, for valve durability, along with design changes intended to improve patient outcomes.
Copyright in the material you requested is held by the American Society of Mechanical Engineers (unless otherwise noted). This email ability is provided as a courtesy, and by using it you agree that you are requesting the material solely for personal, non-commercial use, and that it is subject to the American Society of Mechanical Engineers Terms of Use. The information provided in order to email this topic will not be used to send unsolicited email, nor will it be furnished to third parties. Please refer to the American Society of Mechanical Engineers Privacy Policy for further information ...
Betsy Evans of Leeds General Infirmary in the United Kingdom presents a discussion on TAVI and surgery for prosthetic valve failure. She discusses the background of biological valve implant rate, rate of TAVI, and structural valve deterioration and treatment options. She focuses on two treatment techniques: redo AVR surgery and the TAVI valve-in-valve procedure.. ...
0067] In the embodiments described above relative to FIGS. 7 and 8, the tubular valve segments of stented valves of the invention have a ring of pericardial material that is thicker at one or both of its ends where the material is rolled or folded back on itself. This rolled-back material can overlap or cover the edge of the stent, such as to cover the edge of the stent wires, thereby making the edge or edges of the stented valve smoother. Alternatively, the material may be rolled or folded back in such a way that it does not cover the edge of the stent. For example, a folded portion of material can be positioned so that it is adjacent to an end of a stent and/or the folded portion of material can be positioned to face the interior opening or portion of the stent. In any case, the extra thickness of the material can be beneficial to prevent the stented valve from leaking around its perimeter when implanted in a patient. That is, the rolled or folded areas can help to stabilize the stented valve ...
The Edwards SAPIEN™ THV is a biological heart valve manufactured with treated bovine pericardial tissue that is mounted into a balloon expandable stainless steel open cell stent. The Edwards SAPIEN™ THV is available in two sizes (23 and 26mm) and is designed for transcatheter implantation in patients with regurgitant pulmonary valved conduit with or without stenosis. This device is commercially available and is used according the current IFU ...
For aortic root replacement in annuloaortic ectasia (AAE), an artificial prosthesis is commonly sutured to the aortic annulus (hemodynamic ventriculoaortic junction). We consecutively had 6 cases of aortic root replacement using anatomic ventriculoaortic junction suture. This anatomic ventriculoaortic junction suture is a simplified and practical method for aortic root replacement in the same way as using stentless bioprostheses or homografts ...
For the foreseeable future, bioprosthetic heart valves (BHV) fabricated from xenograft biomaterials will remain the dominant replacement prosthetic valve design...
Since the introduction of the sutureless Perceval® (Sorin Group, Saluggia, Italy) in Europe after CE mark in 2012, the sutureless approach is becoming more and more popular. Sutureless implantation in general is easy, fast and safe, but bears several potential pitfalls. This might result in inferior functional results affecting also clinical outcomes. In our center, more than 300 implant procedures have been performed up to date by mainly two senior surgeons. The technique is in the process of spreading to all surgeons performing aortic valve procedures. Proctored activities are completed at our and other institutions, and wetlab activities are conducted in collaboration with the manufacturers research and development laboratory. This article was written to give a step-by-step advice for surgeons who want to start a sutureless program or even have made limited experience with this approach wanting to reconfirm their technique. The focus is kept on surgical aspects regarding indication, ...
The Carpentier-Edwards Bioprosthetic Valved Conduit (Model 4300) is made from a porcine (pig) aortic valve that has been preserved and mounted on a flexible frame. The flexible frame is composed of a corrosion resistant cobalt chromium metal alloy, silicone rubber, and is covered with polytetrafluoroethylene (PTFE) cloth. The valve is then mounted in a polyester tube. This device can be used to create an extra-cardiac pathway for blood flow in the pulmonic position. This conduit was introduced in the 1970s. ...
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
AIM: Postoperative renal dysfunction after aortic valve replacement is a serious complication. To minimize its occurrence, risk factors have to be identified, and if possible eliminated. METHODS: Of 1000 consecutive patients, who underwent AVR, a file study was performed chi(2)nd logistic regression analysis were performed to study the effect of 24 preoperative, 7 peroperative and 7 postoperative factors on the occurrence of 30-day postoperative worsening of renal function. RESULTS: Fifty-three patients had a 30-day postoperative decrease of renal function. Nine of these patients died, which is significantly more than the mortality without this complication ( ...
Health,... - Offers New Payment Options (10-Pay 15-Pay or 20-Pay) - O... Policies ... - Easy to illustrate sell and service ...BOSTON May 6 /- John Hancock has launched ane...,John,Hancock,Launches,New,Fully,Guaranteed,Whole,Life,Insurance,Product,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
One Piece Hentai with Boa Hancock | Toon sex pic ##00013059694 female ariyon aryion awaiting ejaculation boa hancock breasts censored group sex highres long hair nipples nude one piece very long hair
Discover the best homework help resource for HUM SRVS at Allan Hancock College. Find HUM SRVS study guides, notes, and practice tests for Allan Hancock College.
Hancock county, Kentucky Plants Allergy Info for Research - Complete Online Significant Allergens and Plants Reference for Hancock county in Winter
Hancock county, Ohio Plants Allergy Info for Research - Complete Online Significant Allergens and Plants Reference for Hancock county in Winter
Turkeys Istanbul International Jazz Festival has landed a pair of firsts - Paul Simon will make his first appearance in the country when he closes the event next month (Jul11) and Herbie Hancock will debut his Tribute To Miles show.The...
The Hancock Inn in Hancock, New Hampshire, is one of the oldest inns in New England and home to the delicious Fox Tavern.  Whether you are skiing at Crotched Mountain or a history buff, this quaint bed and breakfast is a must-see. 
Volunteer with Hancock County Habitat for Humanity. Find Hancock County Habitat for Humanity volunteering opportunities at VolunteerMatch!
Portage Health Hospital of Hancock, MI ratings and quality report. Compare Portage Health Hospital to other nearby hospitals in Michigan.
Much has changed in the 21 years since Donna Zirkles physician found a lump during her annual breast exam.. The diagnostic mammogram that followed came back negative. Fortunately, Donnas doctor didnt stop there.. Bless my doctor, Donna said. She called me back and said, Donna, I know theres a lump there. Would you please go get an ultrasound? I actually thought about not doing that, but I trusted her. So, I went for the ultrasound, and I saw it on the screen-a little bitty thing.. Donna is one of a small number of patients - fewer than 10% - who receive a false negative from a mammogram. Her family physician sent her to see Cam Gabrielsen, then the breast surgeon at Hancock Health. Even Dr. Gabrielsen had his doubts about whether the 1.3cm tumor was cancerous.. I had a lumpectomy, Donna said. I hadnt signed off for a mastectomy, because they didnt think it was going to be cancer.. It was. And, three weeks later, she ended up having the mastectomy.. It turns out Donnas cancer was ...
Dr. Michael Carter, MD is a Orthopedic Sports Medicine Surgery Specialist in Hancock, MI. He is affiliated with UP Health System - Portage. He is accepting new patients. Be sure to call ahead with Dr. Carter to book an appointment.
David F. DAlessandro was named president and chief operations officer of John Hancock Mutual Life Insurance. The promotion of the unconventional insurance executive signifies the industrys push to redefine itself.
Vanderbilt-Ingram Cancer Center and the Vanderbilt Institute of Chemical Biology developed out of the work of the Hancock Lab to merit national acclaim for cancer care and translational research that moves discovery from the lab to benefit patients. Today Vanderbilt-Ingram discoveries in cancer genetics are saving lives through precision cancer medicine that precisely targets therapy based on tumor characteristics for patients with melanoma and cancers of the lung, colon and breast. More potent cancer medicines are on the horizon as Vanderbilt-Ingram researchers identify promising candidates by designing novel molecules that effectively inhibit notoriously undruggable mutations found commonly in many cancers and drug-resistant tumors. This research could ultimately lead to treatment for many different types of cancer.. These groundbreaking innovations testify to the wonderful impact achieved by a remarkable family and friends working closely with Vanderbilt scientists. Their collective ...
278 ALLAN HANCOCK PACIFIC EXPEDITIONS VOL. 3 D. 138, dredged in 30 m., south of Tiburon Island, near Turners Island, Jan.; D. 347, in 22 m., off Punta Penasco, Feb. This species is distinct from Halymenia abyssicola of this paper in its thinner fronds (70-130 ft), outer cortex of only one or two layers of small cells, and absence of a thick surface jelly. Halymenia ? abyssicola sp. nov. Frondes planae membranaceae, minime 8 cm. latae, 300 [i crassae, marginibus integris, atro-roseae; glutino superficial! 25-35 p, crasso; corticibus stratis paucis cellularum minutarum dense aggregatarum, 5-7 u, diam. compositis; subcorticibus cellulis majoribus compositis; in medulla filamentis laxe intricatis et crabro con- junctiones stellae-formantes ostendentibus; (frondibus fructuosis nondum visis). Fronds plane, membranous, basal parts unknown, at least 8 cm. broad, with an entire margin, 300 ft thick, deep rose colored; cross section showing a thick surface jelly 25-35 ft thick, a cortical tissue of a few ...
E William Hancock is on CAP Network. CAP Network is a virtual workspace, to support collaboration among faculty, graduate students, postdocs and staff.
Five students from Allan Hancock College will travel to Louisville, Ky., to compete in the SkillsUSA National Championships, which aim to recognize st...
Buy Billy Hancock - Out of the Darkness [CD] at DeepDiscount.com. Music: Folk: 791022261127. Guaranteed Lowest Price. Free Shipping on Orders over $25!
Herbie Hancock  70th birthday bash  Carnegie Hall Bill Cosby  saxophonist Joe Lovano  trumpeter Terence Blanchard  saxophonist Wayne Shorter Miles Davis\\ 1960s quintet...
View the monthly asthma forecast for Hancock, MD from AccuWeather.com and see how your respiratory health will be impacted by the weather
Hancock, E J. and Kilburn, D G., The effects of cyclophosphamide on in vitro cytotoxic responses to a syngeneic tumour. (1982). Subject Strain Bibliography 1982. 988 ...
Nel 1968, partito per la luna di miele in Brasile, al suo ritorno si ammalerà gravemente e Miles Davis sarà costretto a sostituirlo permanentemente con Chick Corea. Lasciato il gruppo di Davis, registra per la Warner lalbum Fat Albert Rotunda, il suo primo disco squisitamente funky, anche colonna sonora dellomonimo cartone animato. Nel 1969 forma un sestetto con cui realizza diversi dischi come The Prisoner. In questo periodo incomincia a interessarsi di strumenti elettronici. Gli album per la Warner Bros segnano il definitivo passaggio nella sfera del funky. Lalbum di transizione è Fat Albert Rotunda al quale seguono Crossings e Sextant (il sound ricorda vagamente Bitches Brew di Miles Davis) per poi passare alla fase funk vera e propria. Lalbum più significativo è Head Hunters nel quale è presente il famoso singolo Chameleon. Questo periodo continuerà fino agli anni ottanta, data nella quale il continuo zigzagare di Hancock da un genere allaltro lo porterà a seguire due progetti ...
CNNs Ryan Young reports from the scene of the Hancock Tower fire, Chicago Fire Spokesman John McNicholas says that five people have been injured.
Looking for exceptional deals on Hancock vacation packages? Save up to $378^ when you bundle your flight and hotel. Book your escape today!
JHML | A complete John Hancock Multifactor Large Cap ETF exchange traded fund overview by MarketWatch. View the latest ETF prices and news for better ETF investing.
Rollout of the Pfizer vaccine could begin in the UK as soon as next month, Matt Hancock has said, with the bulk of the rollout taking place in the New Year.
Look at most relevant Freestyle copilot download websites out of 126 Thousand at KeywordSpace.com. Freestyle copilot download found at freestylediabetes.co.uk, diabeteshealth.com, myfreestyle.com.a...
ABSTRACT. In this paper the problem of recognition of patients intent to move hand prosthesis is addressed. The proposed method is based on recognition of electromiographic (EMG) and mechanomiographic (MMG) biosignals using a multiclassifier system (MCS) working with dynamic ensemble selection (DES) scheme and original concept of competence function. The competence measure is based on relating the response of the classifier with the decision profile of a test object which is evaluated using K nearest objects from the validation set (static mode). Additionally, feedback information coming from bioprosthesis sensors on the correct/incorrect classification is applied to the adjustment of the combining mechanism during MCS operation through adaptive tuning competences of base classifiers depending on their decisions (dynamic mode). Experimental investigations using real data concerning the recognition of five types of grasping movements and computer-simulated procedure of generating feedback ...
To easily remove the old replaceable bioprostheses, its "stent" can be sectioned to dismount its framework and so facilitate ... bioprostheses or "tissue valves"), the replaceable models of implantable heart valve prostheses are made by two or three ... "A new bioprosthesis for aortic and mitral valve replacement: Preliminary evaluation of the Tascon valve". Texas Heart Institute ... In vitro study of a recambiavel bioprosthesis]. Revista da Sociedade de Cardiologia do Estado de São Paulo (in Portuguese). 2 ( ...
2001). "Midterm evaluation of the Tissuemed (Aspire) porcine bioprosthesis: 493 patients, 506 bioprostheses". The Annals of ... 2003). "Ten year experience with Aspire (Tissuemed) porcine bioprosthesis: single centre experience". Cardiovascular Surgery. ...
In this category we find examples such as animal tissue prostheses (xenogeneic bioprosthesis). Xenogeneic heart valves are of ... "In vitro testing of bioprostheses: influence of mechanical stresses and lipids on calcification". The Annals of Thoracic ...
Great damage can be inflicted on a bioprosthesis at the time of its implantation. One of the not so rare causes is allowing the ... Watanabe describes a case of an Ionescu-Shiley bioprosthesis which functioned 24years in the mitral position of a patient. The ... Macro and microscopic pathology studies of failed porcine bioprostheses by Schoen and Cohn showed in detail the process of ... Concerning the surgeon: Correct rinsing of the bioprosthesis prior to implantation, maintaining the moistness of the valve ...
1991). "Twelve-year comparison of a Bjork-Shiley mechanical heart valve with porcine bioprostheses". N Engl J Med. 324 (9): 573 ...
... bioprostheses may have a degeneration problem). Some evidence suggests that there are no significant differences between a ...
... surgery is the replacement of one or more of the heart valves with either an artificial heart valve or a bioprosthesis ( ...
... bioprosthesis MeSH E07.695.110 --- blood vessel prosthesis MeSH E07.695.120 --- bone nails MeSH E07.695.125 --- bone plates ...
... and developed and implanted the first ASEAN bioprosthesis, the PHCA porcine valve. The first patient to be admitted to the PHC ...
Carpentier-Edwards Pericardial Bioprosthesis.' This valve is reported to perform better than its predecessor, the original ...
"Primary safety and effectiveness feasibility study after surgical aortic valve replacement with a new generation bioprosthesis ...
Since the trials are very recent, the long-term effects of this mitral valve bio-prosthesis in humans are currently unknown. ... October 2012). "Tiara: a novel catheter-based mitral valve bioprosthesis: initial experiments and short-term pre-clinical ... February 2014). "Transapical mitral implantation of the Tiara bioprosthesis: pre-clinical results". JACC. Cardiovascular ...
A biomaterial useful for bioprostheses such as bioprosthetic heart valves is provided in which the fixed tissue has improved ... The tissue of the present invention can generally be utilized in any of a number of bioprostheses. For instance, bioprostheses ... The present invention is generally directed to improved bioprostheses and methods for forming the improved bioprostheses. In ... bioprostheses are disclosed including tissues which have a greater elastin content than tissues used in similar bioprostheses ...
The primary objective of the study is the hemodynamic performance of the bioprosthesis at 6 and 12 months after surgery. [ Time ... Hancock II Ultra Porcine Bioprosthesis Hemodynamic Study. This study has been completed. ... bioprosthesis in the aortic position, to analyze the incidence of patient prosthesis mismatch, correlation of gradients, and to ...
Mitroflow aortic bioprosthesis 5-year follow-up: North American Prospective Multicenter Study. Ann Thorac Surg. 2012;94:1198- ... Early Structural Valve Deterioration of the Mitroflow Aortic Bioprosthesis. Tsuyoshi Kaneko, Igor Gosev, Marzia Leacche, John G ... The valve is placed in the supra-annular position compared with the intra-annular position in some of the other bioprostheses. ... Alvarez et al11 reported their series of 491 patients ,70 years of age who received a Mitroflow aortic bioprosthesis. Freedom ...
Percutaneous Aortic CoreValve Prosthesis in a Degenerated Bioprosthesis Prótesis aórtica percutánea CoreValve sobre prótesis ... We report the first case of successful treatment of severe stenosis of a degenerated aortic bioprosthesis using the ... Carpentier-Edwards bioprosthesis) in 2005 to treat aortic stenosis, presented with symptoms of heart failure. Transthoracic and ...
The ATS 3f Aortic Bioprosthesis is the Companys first entry into ... The ATS 3f Aortic Bioprosthesis is the only tissue valve ... that pre...,ATS,Medical,Announces,First,Commercial,Implants,of,the,ATS,3f,Aortic,Bioprosthesis,in,the,United,States,medicine, ... The ATS 3f Aortic Bioprosthesis is the Companys first entry into ... The ATS 3f Aortic Bioprosthesis is the only tissue valve ... The ATS 3f Aortic Bioprosthesis is the Companys first entry into the $400-plus million U.S. tissue valve market. Based on the ...
Reoperation of degenerated bioprostheses has a high mortality risk that increases with the age and associated comorbidities of ... Successful Transapical Transcatheter Valve Implantation Within a Dysfunctional Mitral Bioprosthesis. Arend de Weger, Giuseppe ... Successful Transapical Transcatheter Valve Implantation Within a Dysfunctional Mitral Bioprosthesis. Arend de Weger, Giuseppe ... During the procedure, due to the absence of a radiopaque annular ring, the mitral bioprosthesis was only visible on fluoroscopy ...
Aortic and mitral valve replacement with the Carpentier-Edwards pericardial bioprosthesis: mid-term clinical results. ... durability of this valve is excellent and consider the Carpentier-Edwards pericardial valve as the stented bioprosthesis of ...
Holmes, D., & Mack, M. J. (2017). Aortic Valve Bioprostheses: Leaflet Immobility and Valve Thrombosis. Circulation, 135(18), ... Aortic Valve Bioprostheses : Leaflet Immobility and Valve Thrombosis. / Holmes, David; Mack, Michael J. ... Holmes, D & Mack, MJ 2017, Aortic Valve Bioprostheses: Leaflet Immobility and Valve Thrombosis, Circulation, vol. 135, no. 18 ... Holmes, David ; Mack, Michael J. / Aortic Valve Bioprostheses : Leaflet Immobility and Valve Thrombosis. In: Circulation. 2017 ...
Hemodynamic evaluation of 19-mm Carpentier-Edwards pericardial bioprosthesis in aortic position. Annals of Thoracic Surgery. ... Hemodynamic evaluation of 19-mm Carpentier-Edwards pericardial bioprosthesis in aortic position. :: Annals of Thoracic Surgery ... The aortic Carpentier-Edwards pericardial bioprosthesis offers good long-term clinical outcomes with a low rate of structural ... The aortic Carpentier-Edwards pericardial bioprosthesis offers good long-term clinical outcomes with a low rate of structural ...
Keywords: Aortic valve replacement; Sorin Freedom SOLO bioprosthesis; Torn bioprosthesis Journal Article. 1103 words. ... When the long-term follow-up of the Freedom SOLO bioprosthesis is available, it has to be compared with other bioprosthesis for ... After radiographic and microscopic examination, no clear cause was found for the failure of this Freedom SOLO bioprosthesis. To ... After radiographic and microscopic examination, no clear cause was found for the failure of this Freedom SOLO bioprosthesis. To ...
New CoreValve Evolut 23mm Technology for Treatment of Degenerated Bioprosthesis. Dennis Zavalloni, Mauro De Benedictis, Paolo ... New CoreValve Evolut 23mm Technology for Treatment of Degenerated Bioprosthesis. / Zavalloni, Dennis; De Benedictis, Mauro; ... New CoreValve Evolut 23mm Technology for Treatment of Degenerated Bioprosthesis. In: Heart Lung and Circulation. 2014 ; Vol. 23 ... Fingerprint Dive into the research topics of New CoreValve Evolut 23mm Technology for Treatment of Degenerated Bioprosthesis ...
Brief summary: aortic bioprostheses. Indications: For use in patients whose aortic valvular disease warrants replacement of ... Brief summary: aortic bioprostheses. Indications: For use in patients whose aortic valvular disease warrants replacement of ... Carpentier-Edwards Pericardial Bioprosthesis in Aortic or Mitral Position: a 12-year Experience. Ann Thorac Surg. 1998;66(6 ... Carpentier-Edwards Pericardial Bioprosthesis in Aortic Position: Long-term Follow-up 1980 to 1994. Ann Thorac Surg. 1995;60: ...
Also, its possible that many patients in the Brazilian trial received their bioprosthesis because of rheumatic valvular ...
A composite Dacron graft, which includes the new valve bioprosthesis or prosthesis, is put in place. Then, the coronary ...
Since the trials are very recent, the long-term effects of this mitral valve bio-prosthesis in humans are currently unknown. ... October 2012). "Tiara: a novel catheter-based mitral valve bioprosthesis: initial experiments and short-term pre-clinical ... February 2014). "Transapical mitral implantation of the Tiara bioprosthesis: pre-clinical results". JACC. Cardiovascular ...
Aortic Bioprosthesis. ATS Medical acknowledged the positive clinical results of aortic root dimensions study presented by noted ... Louis, Missouri, and principal in the development of the ATS 3f(R) Aortic Bioprosthesis offered his comments on Dr. Jins ... Aortic Bioprosthesis with its single suture line/3 tab fixation, stentless valves implanted with conventional double suture ...
Subclinical Aortic Valve Bioprosthesis Thrombosis Assessed With 4D CT (SAVORY). The safety and scientific validity of this ... Subclinical Aortic Valve biOprosthesis thRombosis Assessed With 4D Computed tomographY Imaging. Study Start Date :. April 2015 ... Frequency of patients with abnormal aortic valve bioprosthesis leaflet mobility and morphology [ Time Frame: At least 21 days ... The frequency of this potentially ominous phenomenon on both transcatheter and surgical aortic valve bioprosthesis is unknown, ...
When the long-term follow-up of the Freedom SOLO bioprosthesis is available, it has to be compared with other bioprosthesis for ... Patients with TF bioprostheses had higher rates of prolonged mechanical ventilation, whereas patients with the FS bioprosthesis ... Before matching, severe thrombocytopenia (Solo bioprosthesis and 1% with a Perimount bioprosthesis (p Solo (p Solo and ... Case 1: patients with bioprosthesis dysfunction; Case 2: severe aortic stenosis; Case 3: dysfunction of aortic bioprosthesis. ...
The Toronto Root bioprosthesis is safe and provides good clinical and hemodynamic function after full root replacement with or ... The Toronto Root bioprosthesis with BiLinx anticalcification treatment (St. Jude Medical, St. Paul, MN) was introduced into ... received full root replacement at our institution with the Toronto Root bioprosthesis from June 2001 until November 2007. The ...
Aortic Bioprosthesis Structural Valve Dysfunction Other: 18F-Fluoride PET-CT ; CT calcium scoring ; 18F-FDG PET-CT Phase 4 ... Assessment of Osteoblastic Activity With 18F-Fluoride in Aortic Bioprosthesis Structural Valve Dysfunction (SVD) (TEP-SVD). The ... Both 18F-Fluoride and 18F-FDG TBR will be correlated with bioprosthesis calcium scoring and the following echocardiographic ... SVD defined on echocardiography by an alteration of bioprosthesis leaflets function with a mean transvalvular gradient , 20 ...
... on transapical transcatheter mitral valve-in-valve implantation for a failed surgically implanted mitral valve bioprosthesis ... Transapical transcatheter mitral valve-in-valve implantation for a failed surgically implanted mitral valve bioprosthesis. ... 1.4 Transapical transcatheter mitral valve‑in‑valve implantation for a failed surgically implanted mitral valve bioprosthesis ... valve implantation for a failed surgically implanted mitral valve bioprosthesis onto the National Institute for Cardiovascular ...
One-Year Outcomes of Cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry. The European ... Methods and Results-The Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry was designed to assess initial ... One-Year Outcomes of Cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry ... One-Year Outcomes of Cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry ...
... valve-in-valve procedure with a CoreValve prosthesis for the treatment of a severely stenotic degenerated aortic bioprosthesis. ...
... after valve re-replacement for bioprostheses is not well-documented. This research compares the late fate of these two valve ... The fate of bioprostheses (BP) and mechanical prostheses (MP) ... BACKGROUND: The fate of bioprostheses (BP) and mechanical ... Bioprosthesis* / adverse effects. Heart Valve Prosthesis* / adverse effects, classification. Heart Valve Prosthesis ... Next Document: Results of aortic valve replacement with a new supra-annular pericardial stented bioprosthesis.. ...
In this report, the global Vascular Bioprostheses market is valued... ... 103 Pages Report] Check for Discount on Global Vascular Bioprostheses Market Research Report 2018 report by QYResearch Group. ... 1 Vascular Bioprostheses Market Overview. 1.1 Product Overview and Scope of Vascular Bioprostheses. 1.2 Vascular Bioprostheses ... Global Vascular Bioprostheses Market Research Report 2018 Table of Contents. Global Vascular Bioprostheses Market Research ...
A Case of Acute Aortic Regurgitation due to Leaflet Dehiscence of a Carpentier-Edwards Pericardial Bioprosthesis 16 Years after ... A 39-year-old woman, who had undergone aortic valve replacement with a Carpentier-Edwards pericardial bioprosthesis 16 years ...
aortic regurgitation, aortic stenosis, bovine pericardial bioprosthesis, surgical aortic valve replacement Persistent URL. dx. ... One-year outcomes associated with a novel stented bovine pericardial aortic bioprosthesis. Publication. Publication. The ... One-year outcomes associated with a novel stented bovine pericardial aortic bioprosthesis. The Journal of Thoracic and ...
Stentless porcine bioprostheses in the treatment of aortic valve infective endocarditis ... Stentless porcine bioprostheses in the treatment of aortic valve infective endocarditis. Stentless porcine bioprostheses in the ... Stentless aortic bioprostheses: their role in the treatment of aortic endocarditis should not be underestimated. European ... Stentless bioprostheses: a versatile and durable solution in extensive aortic valve endocarditis. European Journal of Cardio- ...
In February 2011, a number of Russian researchers announced plans to create an artificial human body controlled by a neurointerface by the year 2045.
45.1%). The degree of oversizing for all mechanisms of bioprosthesis failure was 9 ± 10% for stentless ViV-TAVR vs. 6 ± 9% for ... Outcomes Following Transcatheter Aortic Valve Replacement for Degenerative Stentless Versus Stented Bioprostheses ... Outcomes Following Transcatheter Aortic Valve Replacement for Degenerative Stentless Versus Stented Bioprostheses ... Outcomes Following Transcatheter Aortic Valve Replacement for Degenerative Stentless Versus Stented Bioprostheses ...
Prima Plus (Edwards Lifesciences) stentless bioprosthesis or the Carpentier-Edwards Perimount stented bioprosthesis (Edwards ... Prospective randomised trial of stented versus stentless bioprosthesis for aortic valve replacement (AVR). ...
Bioprosthesis, Heart valve prosthesis, Multidetector-row computed tomography Persistent URL. dx.doi.org/10.1007/s00330-019- ... Key Points: • Deformation of surgically implanted aortic valve bioprostheses (bio-sAVRs) can be adequately assessed using MDCT ... Surgically implanted aortic valve bioprostheses deform after implantation: insights from computed tomography. Publication. ... Surgically implanted aortic valve bioprostheses deform after implantation: insights from computed tomography. European ...
Transfemoral venous access was obtained, and the tricuspid valve bioprosthesis was crossed with a balloon-tipped pulmonary ... First-in-Human Transcatheter Pulmonic Valve Implantation Through a Tricuspid Valve Bioprosthesis to Treat Native Pulmonary ... First-in-Human Transcatheter Pulmonic Valve Implantation Through a Tricuspid Valve Bioprosthesis to Treat Native Pulmonary ... First-in-Human Transcatheter Pulmonic Valve Implantation Through a Tricuspid Valve Bioprosthesis to Treat Native Pulmonary ...
To form a non-thrombotic surface on the bioprosthesis and to avoid the graft versus host reaction, the most natural way is to ... Fabrication of aortic bioprosthesis by decellularization, fibrin glue coating and re-endothelization: a cell scaffold approach ... Hence, the roles of biological source blood vessel are appreciated (Hansen 2005). The bioprostheses are usually structured in ... These properties are met better toward bioprosthesis and homografts compared to synthetic ones. There are various ways to ...
"Transcatheter valve-in-valve overexpansion for treating a large dysfunctional tricuspid bioprosthesis, Interactive ... Transcatheter valve-in-valve overexpansion for treating a large dysfunctional tricuspid bioprosthesis. Asmarats, Luis; Houde, ... DISCUSSION TVIV implantation within failed tricuspid bioprostheses has emerged as an alternative to surgery in recent years. To ... DISCUSSION TVIV implantation within failed tricuspid bioprostheses has emerged as an alternative to surgery in recent years. To ...
  • Utilizing techniques learned from percutaneous valve implantation procedures, Mayo Clinic physicians have been instrumental in advancing the treatment of patients who have previously undergone surgery to replace the mitral or tricuspid valve with a tissue bioprosthesis, and have published some of the earliest reports and publications on this type of approach. (mayoclinic.org)
  • We report the first case of successful treatment of severe stenosis of a degenerated aortic bioprosthesis using the percutaneous CoreValve prosthesis. (revespcardiol.org)
  • The Carpentier-Edwards PERIMOUNT Magna Ease pericardial aortic bioprosthesis is intended for use in patients whose aortic valvular disease is sufficiently advanced to warrant replacement of their natural valve with a prosthetic one. (edwards.com)
  • Carpentier-Edwards PERIMOUNT pericardial aortic bioprosthesis. (edwards.com)
  • The objective of this clinical study is to evaluate, at six and twelve months, the hemodynamic performance of the HancockÒ Ultra™ bioprosthesis in the aortic position, to analyze the incidence of patient prosthesis mismatch, correlation of gradients, and to ascertain frequency at which a larger valve size is used vs. a patient's debrided annulus diameter. (clinicaltrials.gov)
  • The primary objective of the study is the hemodynamic performance of the bioprosthesis at 6 and 12 months after surgery. (clinicaltrials.gov)
  • However, little in vivo hemodynamic data is available for this bioprosthesis. (elsevier.com)
  • On the other hand, bioprosthetic valves have superior hemodynamic performance but durability of the bioprosthesis limits their use to the elderly, with early onset calcification being the primary cause of biomaterial breakdown. (eurekaselect.com)
  • Leaflet immobility and valve thrombosis have been reported with both transcatheter and surgical aortic valve bioprostheses. (elsevier.com)
  • The aortic Carpentier-Edwards pericardial bioprosthesis offers good long-term clinical outcomes with a low rate of structural deterioration. (elsevier.com)
  • Our hope is that one day this ovarian bioprosthesis is really the ovary of the future,' said Dr Teresa Woodruff , director of the Women's Health Research Institute at Northwestern University's Feinberg School of Medicine, to The Guardian . (bionews.org.uk)
  • We conclude that the mid-term durability of this valve is excellent and consider the Carpentier-Edwards pericardial valve as the stented bioprosthesis of choice both in the aortic and mitral positions for the elderly. (kuleuven.be)
  • The Carpentier-Edwards aortic pericardial valve portfolio is built upon the PERIMOUNT bioprosthesis design. (edwards.com)
  • The type of valve used will depend on the size of the existing bioprosthesis (inner diameter) and nature of the valve dysfunction. (mayoclinic.org)
  • A 60-year-old man with hepatic cirrhosis and portal hypertension, who underwent aortic valve replacement (Carpentier-Edwards bioprosthesis) in 2005 to treat aortic stenosis, presented with symptoms of heart failure. (revespcardiol.org)
  • Sorin expects the unique bioprosthesis to improve procedure visibility for suturing, thereby reducing procedure time and maintaining a learning curve similar to that of a stented valve implant. (medgadget.com)
  • C. Posicionamiento de la válvula Melody dentro de la prótesis biológica desde un enfoque transfemoral con un cable guía posicionado en la rama de la arteria pulmonar distal. (mayoclinic.org)
  • We have analyzed the tissue failure phenomenon in mitral and aortic porcine bioprostheses explanted from the same patient so as to avoid the bias of host factors. (elsevier.com)
  • The 50 bioprostheses of this study were explanted from 25 patients reoperated on because of malfunctioning due to primary tissue failure. (elsevier.com)
  • Mayo Clinic se esfuerza en publicar nuevos materiales traducidos con frecuencia. (mayoclinic.org)
  • A. La angiografía del ventrículo derecho demuestra insuficiencia transvalvular grave con una aparición rápida del contraste en la aurícula derecha. (mayoclinic.org)
  • We have analyzed the tissue failure phenomenon in mitral and aortic porcine bioprostheses explanted from the same patient so as to avoid the bias of host factors. (elsevier.com)
  • Prima Plus (Edwards Lifesciences) stentless bioprosthesis or the Carpentier-Edwards Perimount stented bioprosthesis (Edwards Lifesciences). (isrctn.com)
  • Structural Valve Deterioration in Mitral Replacement Surgery: Comparison of Carpentier-Edwards Supra-Annular Porcine and PERIMOUNT Pericardial Bioprostheses. (edwards.com)
  • Carpentier-Edwards PERIMOUNT pericardial bioprosthesis 16-year results. (edwards.com)
  • The Carpentier-Edwards aortic pericardial valve portfolio is built upon the PERIMOUNT bioprosthesis design. (edwards.com)
  • The Carpentier-Edwards PERIMOUNT Magna Ease pericardial aortic bioprosthesis is intended for use in patients whose aortic valvular disease is sufficiently advanced to warrant replacement of their natural valve with a prosthetic one. (edwards.com)
  • Carpentier-Edwards PERIMOUNT pericardial aortic bioprosthesis. (edwards.com)
  • Between August 2000 and September 2002, 139 patients underwent isolated aortic valve replacement (AVR) with the Mosaic (n = 67) or Perimount (n = 72) bioprosthesis. (qxmd.com)
  • A 39-year-old woman, who had undergone aortic valve replacement with a Carpentier-Edwards pericardial bioprosthesis 16 years previously, was admitted to our hospital with a diagnosis of acute heart failure due to acute aortic regurgitation. (umin.ac.jp)
  • The aortic Carpentier-Edwards pericardial bioprosthesis offers good long-term clinical outcomes with a low rate of structural deterioration. (elsevier.com)
  • Aortic and mitral valve replacement with the Carpentier-Edwards pericardial bioprosthesis: 10-year results. (edwards.com)
  • 15-year experience with the Carpentier-Edwards pericardial bioprosthesis. (edwards.com)
  • Carpentier-Edwards pericardial bioprosthesis in aortic or mitral position: a 12-year experience. (edwards.com)
  • Very late outcomes for mitral valve replacement with the Carpentier-Edwards pericardial bioprosthesis: 25 year follow-up of 450 implantations. (edwards.com)
  • Methods Unadjusted outcome data were collected from the VIVID (Valve-in-Valve International Data) registry between 2007 and 2016 from a total of 1,598 aortic ViV procedures (291 stentless, 1,307 stented bioprostheses). (onlinejacc.org)
  • METHODS: Patients with symptomatic degeneration of surgical aortic bioprostheses at high risk (≥50% major morbidity or mortality) for reoperative surgery were prospectively enrolled in the multicenter PARTNER (Placement of Aortic Transcatheter Valves) 2 VIV trial and continued access registries. (blogspot.com)
  • We describe the first report of an Edwards SAPIEN valve implanted in a tricuspid bioprosthesis from the femoral vein. (worldwidescience.org)
  • After failed aggressive medical therapy and surgical turn down, an Edwards SAPIEN XT valve was deployed in the tricuspid bioprosthesis via the right femoral vein. (worldwidescience.org)
  • Transfemoral venous access was obtained, and the tricuspid valve bioprosthesis was crossed with a balloon-tipped pulmonary artery catheter. (onlinejacc.org)
  • This case illustrates the feasibility of tricuspid valve-in-valve procedures in selected patients with large failed tricuspid bioprostheses. (deepdyve.com)
  • The Porcine Organic Valvular Bioprosthesis is indicated for mitral, aortic, tricuspid or pulmonary valve replacements. (medicalexpo.com)
  • The NaviGate bioprosthesis is a novel self-expanding valved stent designed to treat functional tricuspid regurgitation. (onlinejacc.org)
  • A new CEP bioprosthesis was implanted in the mitral position. (worldwidescience.org)
  • Based on these experiences with aortic bioprostheses, and on the established application of CMR to assess the severity of native mitral stenosis [ 4 , 5 ], it would be desirable to apply this method to bioprostheses implanted in the mitral position. (biomedcentral.com)
  • Deformation of surgically implanted aortic valve bioprostheses (bio-sAVRs) can be adequately assessed using MDCT. (eur.nl)
  • Background Valve-in-valve (ViV) transcatheter aortic replacement (TAVR) is an alternative to redo surgery for patients with a failing aortic bioprosthesis. (onlinejacc.org)
  • These 2 bovine pericardial bioprostheses have been widely adopted at most centres and we aimed to compare TF with FS, the most recently available models of their respective counterparts. (deepdyve.com)
  • A biomaterial useful for bioprostheses such as bioprosthetic heart valves is provided in which the fixed tissue has improved elastic properties. (google.co.uk)
  • The ATS 3f Aortic Bioprosthesis is the only tissue valve that pre. (bio-medicine.org)
  • The ATS 3f Aortic Bioprosthesis is the Company's first entry into the $400-plus million U.S. tissue valve market. (bio-medicine.org)
  • Based on the precept that 'Form Follows Function', the ATS 3f Aortic Bioprosthesis is a revolutionary next generation stentless pericardial aortic tissue valve that is unlike any other valve. (bio-medicine.org)
  • The ATS 3f Aortic Bioprosthesis is the only tissue valve that preserves the sinuses and restores native valve stress distribution and physiologic flow to the entire aortic root," commented Dr. Stewart. (bio-medicine.org)
  • The valve is placed in the supra-annular position compared with the intra-annular position in some of the other bioprostheses. (ahajournals.org)
  • Results of aortic valve replacement with a new supra-annular pericardial stented bioprosthesis. (biomedsearch.com)
  • The Toronto root stentless valve in the subcoronary position is hemodynamically superior to the mosaic stented completely supra-annular bioprosthesis. (qxmd.com)
  • Postoperative outcomes and survival rates were comparable for both bioprostheses. (deepdyve.com)
  • Hydraulic characteristics of heart valve bioprostheses mounted on supporting structures of various rigidity have been studied under physiologic conditions. (worldwidescience.org)
  • n=17) or stenosis (n=7) using balloon-expandable bioprostheses. (eurekamag.com)
  • We have developed a surgical technique by which we were able to ameliorate this troublesome situation in a 79-year-old man with aortic stenosis in whom we had to intraoperatively explant the bioprosthesis that we have put in initially. (elsevier.com)
  • To our knowledge, this is the third failure of a Freedom SOLO bioprosthesis reported in the literature. (worldwidescience.org)
  • When the long-term follow-up of the Freedom SOLO bioprosthesis is available, it has to be compared with other bioprosthesis for long-term durability. (worldwidescience.org)
  • The stentless Freedom Solo aortic bioprosthesis is implanted supraannularly using one running suture line in the sinuses of Valsalva. (worldwidescience.org)
  • St. Jude's (now Abbott) Trifecta® (TF) is a new stented bioprosthesis with externally mounted pericardial leaflets that allow for theoretical optimization of effective orifice area (EOA). (deepdyve.com)
  • In this report, the global Vascular Bioprostheses market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. (reportsnreports.com)
  • Cardiovascular magnetic resonance (CMR) has been proven as an accurate alternative for assessing aortic bioprostheses. (biomedcentral.com)
  • Recently, cardiovascular magnetic resonance (CMR) has been identified as an accurate non-invasive tool for the assessment of the orifice area of bioprostheses implanted in the aortic position. (biomedcentral.com)
  • La misión de la Sociedad Española de Cirugía Torácica y Cardiovascular es asegurar la calidad en el ejercicio de las cirugías torácica y cardiovascular mediante la formación, la promoción de la investigación, el desarrollo y difusión de estándares y guías, y su influencia sobre las políticas sanitarias a nivel nacional. (elsevier.es)
  • 70 years of age who received a Mitroflow aortic bioprosthesis. (ahajournals.org)